Shenzhen Kangtai Biological Products Co., Ltd.
Symbol: 300601.SZ
SHZ
22.57
CNYTržní cena dnes
33.5591
Poměr P/E
0.2598
Poměr PEG
24.02B
MRK Cap
- 0.01%
Výnos DIV
Shenzhen Kangtai Biological Products Co., Ltd. (300601-SZ) finanční výkazy
Rozvaha
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 0 | 1758.9 | 1458.4 | 3549.5 | ||||||||||||
balance-sheet.row.short-term-investments | 0 | 563.4 | 440.8 | 725.6 | ||||||||||||
balance-sheet.row.net-receivables | 0 | 2819.2 | 2414.7 | 1991.2 | ||||||||||||
balance-sheet.row.inventory | 0 | 772.9 | 727.8 | 1058.2 | ||||||||||||
balance-sheet.row.other-current-assets | 0 | 45 | 573.9 | 741.7 | ||||||||||||
balance-sheet.row.total-current-assets | 0 | 5396 | 5174.9 | 7340.7 | ||||||||||||
balance-sheet.row.property-plant-equipment-net | 0 | 5756.9 | 5176.1 | 4116.4 | ||||||||||||
balance-sheet.row.goodwill | 0 | 0 | 0 | 0 | ||||||||||||
balance-sheet.row.intangible-assets | 0 | 504.2 | 475.2 | 736.3 | ||||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 0 | 504.2 | 475.2 | 736.3 | ||||||||||||
balance-sheet.row.long-term-investments | 0 | 2696.2 | 2041.3 | 99.4 | ||||||||||||
balance-sheet.row.tax-assets | 0 | 630.3 | 708.3 | 558.6 | ||||||||||||
balance-sheet.row.other-non-current-assets | 0 | 101.7 | 210.6 | 1297.6 | ||||||||||||
balance-sheet.row.total-non-current-assets | 0 | 9689.4 | 8611.5 | 6808.3 | ||||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | ||||||||||||
balance-sheet.row.total-assets | 0 | 15085.4 | 13786.4 | 14149 | ||||||||||||
balance-sheet.row.account-payables | 0 | 791.2 | 434.1 | 708.2 | ||||||||||||
balance-sheet.row.short-term-debt | 0 | 174.3 | 273.7 | 800.1 | ||||||||||||
balance-sheet.row.tax-payables | 0 | 25.9 | 173.4 | 98.2 | ||||||||||||
balance-sheet.row.long-term-debt-total | 0 | 2372.2 | 2015.7 | 1938 | ||||||||||||
Deferred Revenue Non Current | 0 | 328.7 | 383.1 | 349.5 | ||||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 0 | - | - | - | ||||||||||||
balance-sheet.row.other-current-liab | 0 | 1757.1 | 1600.8 | 2.8 | ||||||||||||
balance-sheet.row.total-non-current-liabilities | 0 | 2463.6 | 2461.2 | 2364.1 | ||||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | ||||||||||||
balance-sheet.row.capital-lease-obligations | 0 | 0 | 0 | 0 | ||||||||||||
balance-sheet.row.total-liab | 0 | 5215 | 4801 | 4982.2 | ||||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | ||||||||||||
balance-sheet.row.common-stock | 0 | 1116.9 | 1120.5 | 687.1 | ||||||||||||
balance-sheet.row.retained-earnings | 0 | 2216.7 | 1641.1 | 2435 | ||||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 0 | 3117.4 | 3036 | 2417.5 | ||||||||||||
balance-sheet.row.other-total-stockholders-equity | 0 | 3090.6 | 3187.7 | 3627.1 | ||||||||||||
balance-sheet.row.total-stockholders-equity | 0 | 9541.7 | 8985.3 | 9166.7 | ||||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 0 | 15085.4 | 13786.4 | 14149 | ||||||||||||
balance-sheet.row.minority-interest | 0 | 0 | 0 | 0 | ||||||||||||
balance-sheet.row.total-equity | 0 | 9541.7 | 8985.3 | 9166.7 | ||||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 0 | - | - | - | ||||||||||||
Total Investments | 0 | 3259.6 | 440.8 | 99.4 | ||||||||||||
balance-sheet.row.total-debt | 0 | 2546.6 | 2289.4 | 2738.1 | ||||||||||||
balance-sheet.row.net-debt | 0 | 1351 | 1271.7 | -811.4 |
Výkaz peněžních toků
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 0 | -132.7 | 1263.4 | 679.2 | |||||||||||
cash-flows.row.depreciation-and-amortization | 0 | 200.9 | 404.7 | 92.9 | |||||||||||
cash-flows.row.deferred-income-tax | 0 | -205.5 | 50.7 | 93.2 | |||||||||||
cash-flows.row.stock-based-compensation | 0 | 10 | 30 | 104.8 | |||||||||||
cash-flows.row.change-in-working-capital | 0 | -604.5 | -275.6 | -461.7 | |||||||||||
cash-flows.row.account-receivables | 0 | -488.8 | 273.9 | -796.5 | |||||||||||
cash-flows.row.inventory | 0 | 220.7 | -746.7 | -209.7 | |||||||||||
cash-flows.row.account-payables | 0 | -131 | 146.5 | 451.3 | |||||||||||
cash-flows.row.other-working-capital | 0 | -205.5 | 50.7 | 93.2 | |||||||||||
cash-flows.row.other-non-cash-items | 0 | 1277.6 | 179.2 | -68.6 | |||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | 0 | -1310.4 | -2540.4 | -1226.7 | |||||||||||
cash-flows.row.acquisitions-net | 0 | 0.1 | 0.2 | 1227.7 | |||||||||||
cash-flows.row.purchases-of-investments | 0 | -3518 | -1100 | -2625 | |||||||||||
cash-flows.row.sales-maturities-of-investments | 0 | 2224.4 | 2198.2 | 13.7 | |||||||||||
cash-flows.row.other-investing-activites | 0 | -2.4 | 1.7 | -1226.7 | |||||||||||
cash-flows.row.net-cash-used-for-investing-activites | 0 | -2606.3 | -1440.3 | -3836.9 | |||||||||||
cash-flows.row.debt-repayment | 0 | -1070.4 | -26.5 | -256 | |||||||||||
cash-flows.row.common-stock-issued | 0 | 132.7 | -2.1 | -1 | |||||||||||
cash-flows.row.common-stock-repurchased | 0 | -20.6 | 2.1 | -0.2 | |||||||||||
cash-flows.row.dividends-paid | 0 | -622.2 | -220.4 | -207.3 | |||||||||||
cash-flows.row.other-financing-activites | 0 | 1115.6 | 2699 | 4243.3 | |||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 0 | -464.9 | 2452.2 | 3778.7 | |||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0 | -1.7 | -1 | 0 | |||||||||||
cash-flows.row.net-change-in-cash | 0 | -2527.1 | 2663.1 | 381.6 | |||||||||||
cash-flows.row.cash-at-end-of-period | 0 | 994.1 | 3521.3 | 858.1 | |||||||||||
cash-flows.row.cash-at-beginning-of-period | 0 | 3521.3 | 858.1 | 476.5 | |||||||||||
cash-flows.row.operating-cash-flow | 0 | 545.7 | 1652.3 | 439.8 | |||||||||||
cash-flows.row.capital-expenditure | 0 | -1310.4 | -2540.4 | -1226.7 | |||||||||||
cash-flows.row.free-cash-flow | 0 | -764.7 | -888.1 | -786.8 |
Řádek výkazu zisku a ztráty
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 0 | 3451.8 | 3157.4 | 3652.1 | ||||||||||||
income-statement-row.row.cost-of-revenue | 0 | 622.8 | 499.9 | 986.4 | ||||||||||||
income-statement-row.row.gross-profit | 0 | 2829.1 | 2657.5 | 2665.7 | ||||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | ||||||||||||
income-statement-row.row.research-development | 0 | - | - | - | ||||||||||||
income-statement-row.row.selling-general-administrative | 0 | - | - | - | ||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | ||||||||||||
income-statement-row.row.other-expenses | 0 | -118.8 | 74.4 | 73.9 | ||||||||||||
income-statement-row.row.operating-expenses | 0 | 2054.2 | 2020.8 | 1071.9 | ||||||||||||
income-statement-row.row.cost-and-expenses | 0 | 2677 | 2520.8 | 2058.4 | ||||||||||||
income-statement-row.row.interest-income | 0 | 115.6 | 132.6 | 114.9 | ||||||||||||
income-statement-row.row.interest-expense | 0 | 113.7 | 109 | 54.5 | ||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | ||||||||||||
income-statement-row.row.total-other-income-expensenet | 0 | 165.5 | -1085.3 | -13 | ||||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | ||||||||||||
income-statement-row.row.other-operating-expenses | 0 | -118.8 | 74.4 | 73.9 | ||||||||||||
income-statement-row.row.total-operating-expenses | 0 | 165.5 | -1085.3 | -13 | ||||||||||||
income-statement-row.row.interest-expense | 0 | 113.7 | 109 | 54.5 | ||||||||||||
income-statement-row.row.depreciation-and-amortization | 0 | 240.7 | 200.9 | 676.6 | ||||||||||||
income-statement-row.row.ebitda-caps | 0 | - | - | - | ||||||||||||
income-statement-row.row.operating-income | 0 | 774.8 | 747 | 1452.2 | ||||||||||||
income-statement-row.row.income-before-tax | 0 | 940.3 | -338.2 | 1439.2 | ||||||||||||
income-statement-row.row.income-tax-expense | 0 | 79 | -205.5 | 175.9 | ||||||||||||
income-statement-row.row.net-income | 0 | 861.3 | -132.7 | 1263.4 |
Často kladené otázky
Co je Shenzhen Kangtai Biological Products Co., Ltd. (300601.SZ) celková aktiva?
Shenzhen Kangtai Biological Products Co., Ltd. (300601.SZ) celková aktiva jsou 15085358535.000.
Jaký je roční obrat podniku?
Roční příjmy jsou N/A.
Jaké je ziskové rozpětí podniku?
Zisková marže firmy je 0.832.
Jaký je volný peněžní tok podniku?
Volný peněžní tok je 0.165.
Jaká je čistá zisková marže podniku?
Čistá zisková marže je 0.224.
Jaké jsou celkové tržby podniku?
Celkové příjmy jsou 0.213.
Co je Shenzhen Kangtai Biological Products Co., Ltd. (300601.SZ) čistý zisk (čistý příjem)?
Čistý zisk (čistý příjem) je 861303903.000.
Jaký je celkový dluh podniku?
Celkový dluh je 2546554090.000.
Jaké je číslo provozních nákladů?
Provozní výdaje jsou 2054244031.000.
Jaké je číslo peněžních prostředků firmy?
Peněžní prostředky podniku jsou 0.000.